Prime Medicine: Gene Editing Company, Risky Investment
Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.
inc426h
Flipkart’s IPO Gameplan: How The $36 Bn Ecommerce Giant Is Gearing Up
Walmart-backed Flipkart wants to shed its foreign image ahead of a mega IPO and the $36 Bn giant has taken calculated steps ...
inc422h
INR 2,500 Cr Revenue, IPO In Motion: How Razorpay Is Prepping For D-Street
IPO-bound Razorpay CEO Harshil Mathur on what it took to get the fintech giant ready for the public listing - from governance ...
PVR Inox Q3 Results: Net profit jumps 180% YoY to Rs 36 crore, revenue grows 11%
PVR Inox reported 180% YoY profit growth to Rs 35.9 crore in Q3 FY25, with revenue rising 11.1% YoY to Rs 1,717.3 crore.